Loading…
Antibody Conjugates and Therapeutic Strategies
Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and inflammatory diseases. Antibodies can be used to exert...
Saved in:
| Published in: | Molecular interventions 2005-12, Vol.5 (6), p.368-380 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c310t-21997107ab92e85776b0f820a1639b235cffd22e801e7aed4ff51f40216a1d8c3 |
|---|---|
| cites | |
| container_end_page | 380 |
| container_issue | 6 |
| container_start_page | 368 |
| container_title | Molecular interventions |
| container_volume | 5 |
| creator | McCarron, Paul A Olwill, Shane A Marouf, Waleed M Y Buick, Richard J Walker, Brian Scott, Christopher J |
| description | Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile
molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and
inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug
molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order
to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review
we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules. |
| doi_str_mv | 10.1124/mi.5.6.9 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1124_mi_5_6_9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16394252</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-21997107ab92e85776b0f820a1639b235cffd22e801e7aed4ff51f40216a1d8c3</originalsourceid><addsrcrecordid>eNpFj0tLxDAUhYMozjgK_gLpwoWb1tw82nQ5FF8w4MJxHdI2aTNMHyQtMv_e1g64OpdzPs7lIHQPOAIg7LmxEY_iKL1Aa-CMhoQzcTnflIWYCrZCN94fMAaRcHqNVhDTlBFO1ijatoPNu_IUZF17GCs1aB-otgz2tXaq1-Ngi-BrcJNfWe1v0ZVRR6_vzrpB368v--w93H2-fWTbXVhQwENIIE0TwInKU6IFT5I4x0YQrObHOaG8MKYkU4RBJ0qXzBgOhmECsYJSFHSDnpbewnXeO21k72yj3EkClvNk2VjJZSzTCX1Y0H7MG13-g-eNE_C4ALWt6h_rtOxr5RpVdMeuOv210FjQX307XSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Antibody Conjugates and Therapeutic Strategies</title><source>CLOCKSS</source><creator>McCarron, Paul A ; Olwill, Shane A ; Marouf, Waleed M Y ; Buick, Richard J ; Walker, Brian ; Scott, Christopher J</creator><creatorcontrib>McCarron, Paul A ; Olwill, Shane A ; Marouf, Waleed M Y ; Buick, Richard J ; Walker, Brian ; Scott, Christopher J</creatorcontrib><description>Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile
molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and
inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug
molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order
to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review
we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.</description><identifier>ISSN: 1534-0384</identifier><identifier>EISSN: 1543-2548</identifier><identifier>DOI: 10.1124/mi.5.6.9</identifier><identifier>PMID: 16394252</identifier><language>eng</language><publisher>United States: American Society for Pharmacology and Experimental Therapeutics</publisher><subject>Animals ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - therapeutic use ; Drug Carriers - chemistry ; Drug Delivery Systems ; Humans ; Immunoconjugates - administration & dosage ; Immunoconjugates - chemistry ; Immunoconjugates - therapeutic use ; Immunotherapy ; Immunotoxins - administration & dosage ; Immunotoxins - chemistry ; Immunotoxins - therapeutic use ; Mice ; Nanostructures ; Peptides - administration & dosage ; Peptides - chemistry ; Peptides - therapeutic use ; Radioisotopes - therapeutic use ; Recombinant Proteins - administration & dosage ; Recombinant Proteins - chemistry ; Recombinant Proteins - therapeutic use</subject><ispartof>Molecular interventions, 2005-12, Vol.5 (6), p.368-380</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c310t-21997107ab92e85776b0f820a1639b235cffd22e801e7aed4ff51f40216a1d8c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16394252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>McCarron, Paul A</creatorcontrib><creatorcontrib>Olwill, Shane A</creatorcontrib><creatorcontrib>Marouf, Waleed M Y</creatorcontrib><creatorcontrib>Buick, Richard J</creatorcontrib><creatorcontrib>Walker, Brian</creatorcontrib><creatorcontrib>Scott, Christopher J</creatorcontrib><title>Antibody Conjugates and Therapeutic Strategies</title><title>Molecular interventions</title><addtitle>Mol Interv</addtitle><description>Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile
molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and
inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug
molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order
to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review
we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.</description><subject>Animals</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Immunoconjugates - administration & dosage</subject><subject>Immunoconjugates - chemistry</subject><subject>Immunoconjugates - therapeutic use</subject><subject>Immunotherapy</subject><subject>Immunotoxins - administration & dosage</subject><subject>Immunotoxins - chemistry</subject><subject>Immunotoxins - therapeutic use</subject><subject>Mice</subject><subject>Nanostructures</subject><subject>Peptides - administration & dosage</subject><subject>Peptides - chemistry</subject><subject>Peptides - therapeutic use</subject><subject>Radioisotopes - therapeutic use</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recombinant Proteins - chemistry</subject><subject>Recombinant Proteins - therapeutic use</subject><issn>1534-0384</issn><issn>1543-2548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><recordid>eNpFj0tLxDAUhYMozjgK_gLpwoWb1tw82nQ5FF8w4MJxHdI2aTNMHyQtMv_e1g64OpdzPs7lIHQPOAIg7LmxEY_iKL1Aa-CMhoQzcTnflIWYCrZCN94fMAaRcHqNVhDTlBFO1ijatoPNu_IUZF17GCs1aB-otgz2tXaq1-Ngi-BrcJNfWe1v0ZVRR6_vzrpB368v--w93H2-fWTbXVhQwENIIE0TwInKU6IFT5I4x0YQrObHOaG8MKYkU4RBJ0qXzBgOhmECsYJSFHSDnpbewnXeO21k72yj3EkClvNk2VjJZSzTCX1Y0H7MG13-g-eNE_C4ALWt6h_rtOxr5RpVdMeuOv210FjQX307XSg</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>McCarron, Paul A</creator><creator>Olwill, Shane A</creator><creator>Marouf, Waleed M Y</creator><creator>Buick, Richard J</creator><creator>Walker, Brian</creator><creator>Scott, Christopher J</creator><general>American Society for Pharmacology and Experimental Therapeutics</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20051201</creationdate><title>Antibody Conjugates and Therapeutic Strategies</title><author>McCarron, Paul A ; Olwill, Shane A ; Marouf, Waleed M Y ; Buick, Richard J ; Walker, Brian ; Scott, Christopher J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-21997107ab92e85776b0f820a1639b235cffd22e801e7aed4ff51f40216a1d8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Immunoconjugates - administration & dosage</topic><topic>Immunoconjugates - chemistry</topic><topic>Immunoconjugates - therapeutic use</topic><topic>Immunotherapy</topic><topic>Immunotoxins - administration & dosage</topic><topic>Immunotoxins - chemistry</topic><topic>Immunotoxins - therapeutic use</topic><topic>Mice</topic><topic>Nanostructures</topic><topic>Peptides - administration & dosage</topic><topic>Peptides - chemistry</topic><topic>Peptides - therapeutic use</topic><topic>Radioisotopes - therapeutic use</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recombinant Proteins - chemistry</topic><topic>Recombinant Proteins - therapeutic use</topic><toplevel>online_resources</toplevel><creatorcontrib>McCarron, Paul A</creatorcontrib><creatorcontrib>Olwill, Shane A</creatorcontrib><creatorcontrib>Marouf, Waleed M Y</creatorcontrib><creatorcontrib>Buick, Richard J</creatorcontrib><creatorcontrib>Walker, Brian</creatorcontrib><creatorcontrib>Scott, Christopher J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Molecular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>McCarron, Paul A</au><au>Olwill, Shane A</au><au>Marouf, Waleed M Y</au><au>Buick, Richard J</au><au>Walker, Brian</au><au>Scott, Christopher J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibody Conjugates and Therapeutic Strategies</atitle><jtitle>Molecular interventions</jtitle><addtitle>Mol Interv</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>5</volume><issue>6</issue><spage>368</spage><epage>380</epage><pages>368-380</pages><issn>1534-0384</issn><eissn>1543-2548</eissn><abstract>Immunotherapeutics represent the largest group of molecules currently in development as new drug entities. These versatile
molecules are being investigated for the treatment of a range of pathological conditions including cancer, infectious and
inflammatory diseases. Antibodies can be used to exert biological effects themselves or as delivery agents of conjugated drug
molecules. Site-specific delivery of therapeutic agents has been an ultimate goal of the pharmaceutical industry in order
to maximize drug action and minimize side effects. Antibodies have the potential to realize this objective and in this review
we will examine some of the main strategies currently being employed for the development of these diverse therapeutic molecules.</abstract><cop>United States</cop><pub>American Society for Pharmacology and Experimental Therapeutics</pub><pmid>16394252</pmid><doi>10.1124/mi.5.6.9</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1534-0384 |
| ispartof | Molecular interventions, 2005-12, Vol.5 (6), p.368-380 |
| issn | 1534-0384 1543-2548 |
| language | eng |
| recordid | cdi_crossref_primary_10_1124_mi_5_6_9 |
| source | CLOCKSS |
| subjects | Animals Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - therapeutic use Antineoplastic Agents - administration & dosage Antineoplastic Agents - chemistry Antineoplastic Agents - therapeutic use Drug Carriers - chemistry Drug Delivery Systems Humans Immunoconjugates - administration & dosage Immunoconjugates - chemistry Immunoconjugates - therapeutic use Immunotherapy Immunotoxins - administration & dosage Immunotoxins - chemistry Immunotoxins - therapeutic use Mice Nanostructures Peptides - administration & dosage Peptides - chemistry Peptides - therapeutic use Radioisotopes - therapeutic use Recombinant Proteins - administration & dosage Recombinant Proteins - chemistry Recombinant Proteins - therapeutic use |
| title | Antibody Conjugates and Therapeutic Strategies |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A28%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibody%20Conjugates%20and%20Therapeutic%20Strategies&rft.jtitle=Molecular%20interventions&rft.au=McCarron,%20Paul%20A&rft.date=2005-12-01&rft.volume=5&rft.issue=6&rft.spage=368&rft.epage=380&rft.pages=368-380&rft.issn=1534-0384&rft.eissn=1543-2548&rft_id=info:doi/10.1124/mi.5.6.9&rft_dat=%3Cpubmed_cross%3E16394252%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c310t-21997107ab92e85776b0f820a1639b235cffd22e801e7aed4ff51f40216a1d8c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/16394252&rfr_iscdi=true |